Amiyangoda G, Antonypillai C N, Gunatilake S S C, Weerathunge T T, Ediriweera D, Kosgallana S G P D, Jayawardana R D P, Thissera H A N D, Emalka W J, Daraniyagala H U
Department of Pharmacology, Faculty of Medicine, University of Peradeniya, Sri Lanka.
Diabetes and Endocrine Unit, National Hospital, Kandy, Sri Lanka.
Endocr Connect. 2024 Sep 25;13(10). doi: 10.1530/EC-24-0277. Print 2024 Oct 1.
Refractory hypothyroidism is associated with high morbidity and increased healthcare expenditure. In general, the use of the levothyroxine absorption test looks promising in evaluating refractory hypothyroidism but has shown significant variability in protocols in multiple settings. We intended to assess the usefulness of the levothyroxine absorption test in a low-resource setting and to assess the factors associated with refractory hypothyroidism. A cross-sectional study among age-matched 25 cases of refractory hypothyroidism and 24 treatment-responsive hypothyroid controls was conducted. A supervised levothyroxine absorption test was performed with levothyroxine 1000 μg tablets after a 10-h fast, and serum free tetraiodothyronine (FT4) levels were measured at 0, 1, 2, 3, 4, and 5 h. Descriptive statistics, chi-square test, Student's t-test, and logistic regression were used in the analysis. Results showed no significant difference in age, body weight, etiology of hypothyroidism, interfering medications, thyroxine storage, and ingestion technique in cases and controls. Cases had a longer duration of hypothyroidism and males had a higher peak FT4 concentration. During pooled analysis, serum FT4 peaked at 3 h with an increment of 149.4% (128.4-170.5%) from baseline and plateaued thereafter. The absolute value of FT4 at 3 h was 41.59 (s.d. 14.14) pmol/L (3.23 ng/dL). We concluded that there was no significant difference in the pattern of levothyroxine absorption in both groups. The most common cause of refractory disease was pseudo-malabsorption. Rapid supervised levothyroxine absorption test with two blood samples for FT4 at baseline and at the peak of absorption (3 h) is simple, convenient, and cost-effective, particularly in low-resource settings.
难治性甲状腺功能减退症与高发病率及医疗费用增加相关。一般而言,左甲状腺素吸收试验在评估难治性甲状腺功能减退症方面似乎很有前景,但在多个环境中的方案显示出显著差异。我们旨在评估左甲状腺素吸收试验在资源匮乏环境中的实用性,并评估与难治性甲状腺功能减退症相关的因素。对年龄匹配的25例难治性甲状腺功能减退症患者和24例治疗反应性甲状腺功能减退症对照进行了一项横断面研究。在禁食10小时后,用1000μg左甲状腺素片进行有监督的左甲状腺素吸收试验,并在0、1、2、3、4和5小时测量血清游离甲状腺素(FT4)水平。分析中使用了描述性统计、卡方检验、学生t检验和逻辑回归。结果显示,病例组和对照组在年龄、体重、甲状腺功能减退症病因、干扰药物、甲状腺素储存和摄入技术方面无显著差异。病例组甲状腺功能减退症病程较长,男性FT4峰值浓度较高。在汇总分析中,血清FT4在3小时达到峰值,较基线增加149.4%(128.4-170.5%),此后趋于平稳。3小时时FT4的绝对值为41.59(标准差14.14)pmol/L(3.23 ng/dL)。我们得出结论,两组左甲状腺素吸收模式无显著差异。难治性疾病最常见的原因是假性吸收不良。在基线和吸收峰值(3小时)采集两份血样检测FT4的快速有监督左甲状腺素吸收试验简单、方便且具有成本效益,尤其在资源匮乏的环境中。